{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:11:21Z","timestamp":1773277881003,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.clml.2019.11.021","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T19:46:20Z","timestamp":1580931980000},"page":"e375-e381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma"],"prefix":"10.1016","volume":"20","author":[{"given":"Vedia","family":"Ozturk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysun Senturk","family":"Yikilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aydan","family":"Kilicarslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sule Mine","family":"Bakanay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sema","family":"Akinci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130mdat","family":"Dilek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.11.021_bib1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.021_bib2","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.11.021_bib3","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.11.021_bib4","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin Lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.11.021_bib5","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2019.11.021_bib6","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clml.2019.11.021_bib7","doi-asserted-by":"crossref","first-page":"111ra120","DOI":"10.1126\/scitranslmed.3003130","article-title":"The PDL1-PD1 axis converts human TH1 cells into regulatory T cells","volume":"3","author":"Amarnath","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clml.2019.11.021_bib8","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2017-06-781989","article-title":"Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma","volume":"130","author":"Liu","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.021_bib9","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1182\/bloodadvances.2017006346","article-title":"High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome","volume":"1","author":"Hollander","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2019.11.021_bib10","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1007\/s13277-015-4622-5","article-title":"Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma","volume":"37","author":"Koh","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.clml.2019.11.021_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2018-02-833806","article-title":"Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?","volume":"132","author":"Carbone","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.021_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.029","article-title":"Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes","volume":"71","author":"Panjwani","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clml.2019.11.021_bib13","doi-asserted-by":"crossref","first-page":"e622","DOI":"10.1038\/bcj.2017.102","article-title":"The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor","volume":"8","author":"Wu","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2019.11.021_bib14","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2019.11.021_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/annonc\/11.suppl_1.S3","article-title":"Lymphoma classification--from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms","volume":"11","author":"Harris","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.11.021_bib16","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.11.021_bib17","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A\u00a0prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2019.11.021_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/annonc\/13.S1.11","article-title":"Biology of Hodgkin's lymphoma","volume":"13","author":"K\u00fcppers","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.11.021_bib19","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.11.021_bib20","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.4049\/jimmunol.181.10.6738","article-title":"The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands","volume":"181","author":"Kinter","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2019.11.021_bib21","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1158\/1078-0432.CCR-10-3327","article-title":"The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma","volume":"17","author":"Hohaus","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2019.11.021_bib22","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/his.13475","article-title":"Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells","volume":"72","author":"Sakakibara","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.clml.2019.11.021_bib23","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1200\/JCO.2005.02.6310","article-title":"Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study","volume":"23","author":"Keegan","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.11.021_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.arcmed.2014.06.001","article-title":"Prevalence and prognostic significance of Epstein-Barr virus infection in classical Hodgkin's lymphoma: a meta-analysis","volume":"45","author":"Lee","year":"2014","journal-title":"Arch Med Res"},{"key":"10.1016\/j.clml.2019.11.021_bib25","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/pin.12175","article-title":"Prognostic significance of CD20 expression and Epstein-Barr virus (EBV) association in classical Hodgkin lymphoma in Japan: a clinicopathologic study","volume":"64","author":"Elsayed","year":"2014","journal-title":"Pathol Int"},{"key":"10.1016\/j.clml.2019.11.021_bib26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12985-017-0715-7","article-title":"Epstein-Barr virus and cytomegalovirus infections and their clinical relevance in Egyptian leukemic pediatric patients","volume":"14","author":"Loutfy","year":"2017","journal-title":"Virol J"},{"key":"10.1016\/j.clml.2019.11.021_bib27","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00277-015-2403-2","article-title":"Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma","volume":"94","author":"Paydas","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.11.021_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.humpath.2016.03.005","article-title":"Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas","volume":"54","author":"Menter","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clml.2019.11.021_bib29","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2008-07-168096","article-title":"Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome","volume":"113","author":"Chetaille","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.021_bib30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/PAI.0000000000000200","article-title":"Expression of TIA1 and PAX5 in classical Hodgkin lymphoma at initial diagnosis may predict clinical outcome","volume":"24","author":"Nguyen","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.clml.2019.11.021_bib31","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s00277-017-3115-6","article-title":"PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma","volume":"96","author":"Koh","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.11.021_bib32","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood-2013-06-508044","article-title":"Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells","volume":"122","author":"Greaves","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.11.021_bib33","doi-asserted-by":"crossref","first-page":"e0204870","DOI":"10.1371\/journal.pone.0204870","article-title":"Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma","volume":"13","author":"Hollander","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2019.11.021_bib34","doi-asserted-by":"crossref","first-page":"e27571","DOI":"10.1002\/pbc.27571","article-title":"Expression of PD-1\/PD-L1 in children's classical Hodgkin lymphoma","volume":"66","author":"Dilly-Feldis","year":"2019","journal-title":"Pediatr Blood Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019322116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019322116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:44Z","timestamp":1761870824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019322116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S2152265019322116"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.11.021","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}